BALANCES AND TRANSACTIONS WITH RELATED PARTIES AND KEY OFFICERS

12 Months Ended

Dec. 31, 2020

Disclosure of transactions between related parties [abstract]

BALANCES AND TRANSACTIONS WITH RELATED PARTIES AND KEY OFFICERS

NOTE 24:- BALANCES AND TRANSACTIONS WITH RELATED PARTIES AND KEY OFFICERS

a. Related parties consist of:

• Clal Biotechnologies Industries Ltd.- Parent Company.

• Directors of the Company.

• CureTech Ltd.-Sister Company.

b. Balances of related parties:

	Other Payables
Parent Company (1):
As of December 31, 2019		119
As of December 31, 2020		138
Other related parties:
As of December 31, 2019		95
As of December 31, 2020		86

c. Transactions with related parties:

	Professional Fee (1)		Rent expenses and other
Parent company:
2018		44		292
2019		52		415
2020		54		446
Other related parties:
2018		162		(246	)
2019		249		(59	)
2020		272		-

(1) Professional fees do not include short-term employee benefits and share-based compensation to one of the Company's shareholders, who is a key officer, in the amounts of $537,  $450 and $486 for the years 2018, 2019 and 2020, respectively, as well as payment for the purchasing of a patent in amount of $12 in 2018.

d. Compensation of officers of the Company:
The following amounts disclosed in the table are recognized as an expense during the reporting period related to officers:

	Year ended December 31,
	2018		2019		2020
Short-term employee benefits (*)		2,304		2,533		1,993
Share-based compensation		276		565		467
		2,580		3,098		2,460
Number of officers		6		7		5

(*) The amount for 2019 includes one-time payments for previous-CEO on the amount of $196.

In December 2007, the Company's board of directors approved one‑time bonus payments to the Chief Medical Officer in the amounts of $ 120, to be paid upon achieving marketing approval in the United States.